MA39361A1 - Dispersion solide amorphe comprenant un taxane, comprimé contenant la dispersion, et méthode de préparation associée - Google Patents
Dispersion solide amorphe comprenant un taxane, comprimé contenant la dispersion, et méthode de préparation associéeInfo
- Publication number
- MA39361A1 MA39361A1 MA39361A MA39361A MA39361A1 MA 39361 A1 MA39361 A1 MA 39361A1 MA 39361 A MA39361 A MA 39361A MA 39361 A MA39361 A MA 39361A MA 39361 A1 MA39361 A1 MA 39361A1
- Authority
- MA
- Morocco
- Prior art keywords
- dispersion
- amorphous solid
- taxane
- solid dispersion
- preparation
- Prior art date
Links
- 239000007962 solid dispersion Substances 0.000 title abstract 4
- 229940123237 Taxane Drugs 0.000 title abstract 2
- 239000006185 dispersion Substances 0.000 title abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000008180 pharmaceutical surfactant Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une dispersion solide amorphe comprenant un taxane ou un sel pharmaceutiquement acceptable de celui-ci, un polymère acceptable sur le plan pharmaceutique, et un tensioactif acceptable sur le plan pharmaceutique, ladite dispersion présentant une plus grande solubilité. L'invention concerne également une méthode de préparation de la dispersion solide. La présente invention concerne également un comprimé ayant une bonne solubilité, une bonne biodisponibilité et une bonne stabilité, qui comprend la dispersion solide amorphe, un excipient intragranulaire et un excipient extragranulaire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2014/002734 WO2015152433A1 (fr) | 2014-03-31 | 2014-03-31 | Dispersion solide amorphe comprenant du paclitaxel, comprimé la comprenant, et son procédé de préparation |
PCT/KR2015/002756 WO2015152544A1 (fr) | 2014-03-31 | 2015-03-20 | Dispersion solide amorphe comprenant un taxane, comprimé contenant la dispersion, et méthode de préparation associée |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39361A1 true MA39361A1 (fr) | 2017-06-30 |
MA39361B1 MA39361B1 (fr) | 2018-06-29 |
Family
ID=54240734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39361A MA39361B1 (fr) | 2014-03-31 | 2015-03-20 | Dispersion solide amorphe comprenant un taxane, comprimé contenant la dispersion, et méthode de préparation associée |
Country Status (33)
Country | Link |
---|---|
US (1) | US9867801B2 (fr) |
EP (1) | EP3125872B1 (fr) |
JP (1) | JP6539675B2 (fr) |
KR (1) | KR101851571B1 (fr) |
CN (1) | CN106255496B (fr) |
AR (1) | AR099886A1 (fr) |
AU (1) | AU2015242738B2 (fr) |
BR (1) | BR112016022528B1 (fr) |
CA (1) | CA2944438C (fr) |
CL (1) | CL2016002441A1 (fr) |
CU (1) | CU24486B1 (fr) |
DK (1) | DK3125872T3 (fr) |
DO (1) | DOP2016000262A (fr) |
ES (1) | ES2748686T3 (fr) |
GT (1) | GT201600208A (fr) |
HU (1) | HUE046616T2 (fr) |
IL (1) | IL247977B (fr) |
LT (1) | LT3125872T (fr) |
MA (1) | MA39361B1 (fr) |
MX (1) | MX2016012596A (fr) |
MY (1) | MY175387A (fr) |
PE (1) | PE20161477A1 (fr) |
PH (1) | PH12016501825A1 (fr) |
PL (1) | PL3125872T3 (fr) |
PT (1) | PT3125872T (fr) |
RU (1) | RU2684632C2 (fr) |
SA (1) | SA516371952B1 (fr) |
SG (1) | SG11201607456RA (fr) |
SI (1) | SI3125872T1 (fr) |
TW (1) | TWI706793B (fr) |
UA (1) | UA117610C2 (fr) |
UY (1) | UY36055A (fr) |
WO (2) | WO2015152433A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017091373A1 (fr) * | 2015-11-25 | 2017-06-01 | Patheon Development Services Inc. | Granulés à dispersion amorphe et formes pharmaceutiques destinées à la voie orale |
CN109069460A (zh) * | 2016-05-09 | 2018-12-21 | 分散技术有限责任公司 | 改进的药物制剂 |
CN106955288B (zh) * | 2017-03-30 | 2020-01-10 | 复旦大学附属中山医院 | Fxr激动剂在制备治疗脂肪肉瘤相关疾病药物中的用途 |
TWI833710B (zh) * | 2017-10-06 | 2024-03-01 | 香港商慧源香港創新有限公司 | 高單位含量口服型紫杉烷組合物及方法 |
CN111511365A (zh) * | 2017-11-10 | 2020-08-07 | 分散技术有限责任公司 | 改进的药物制剂 |
KR20210120039A (ko) * | 2019-01-25 | 2021-10-06 | 베이진 엘티디 | B-raf 키나제 이합체 억제제의 안정적인 고체 분산액, 이의 제조 방법 및 용도 |
CN109851593B (zh) * | 2019-02-01 | 2021-04-16 | 沈阳药科大学 | 基于淋巴介导转运的甘油三酯前药及其制备方法 |
CN110105368B (zh) * | 2019-05-09 | 2022-01-07 | 上海大学 | 去氧紫杉烷类似物及其制备方法 |
WO2021177930A1 (fr) * | 2020-03-06 | 2021-09-10 | Vyshnevskyy Ihor Anatoliyovych | Composition pharmaceutique à solubilité accrue de la gespéridine et son procédé de préparation |
CN116964044A (zh) | 2020-10-07 | 2023-10-27 | 希华医药有限公司 | 乙酰胺基-苯基四唑衍生物及其使用方法 |
EP4358942A1 (fr) * | 2021-06-23 | 2024-05-01 | Blueprint Medicines Corporation | Compositions pharmaceutiques d'un inhibiteur du récepteur du facteur de croissance épidermique |
WO2023154171A1 (fr) * | 2022-02-14 | 2023-08-17 | Purdue Research Foundation | Sels polymères destinés à améliorer l'administration de médicament à partir de dispersions solides amorphes |
AU2022368370A1 (en) * | 2022-03-08 | 2023-09-28 | Cnpharm Co., Ltd. | Pharmaceutical composition containing docetaxel or pharmaceutically acceptable salt thereof and preparation method therefor |
CN115429766B (zh) * | 2022-09-08 | 2023-10-27 | 江苏集萃新型药物制剂技术研究所有限公司 | 淫羊藿苷固体分散体、复方药物双层片剂及其制备方法与应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2294981C (fr) | 1997-06-27 | 2012-04-03 | Vivorx Pharmaceuticals, Inc. | Nouvelles formulations d'agents pharmacologiques, leurs procedes de preparation et d'utilisation |
US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
KR20030041577A (ko) * | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
CA2540104A1 (fr) * | 2003-09-30 | 2005-04-07 | Solubest Ltd. | Nanoparticules hydrosolubles et leur procede de production |
WO2006046623A1 (fr) * | 2004-10-25 | 2006-05-04 | Japan Tobacco Inc. | Préparation médicinale solide améliorée en termes de solubilité et de stabilité et procédé servant à produire celle-ci |
CN1840196A (zh) * | 2006-01-27 | 2006-10-04 | 无锡杰西医药科技有限公司 | 一种适用于难溶性药物的分散剂 |
CN101340896A (zh) * | 2005-12-22 | 2009-01-07 | 特瓦制药工业有限公司 | 含有低溶解性药物的压缩的固体剂型和其制备方法 |
US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
GB0716591D0 (en) | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
CA2696622C (fr) * | 2007-08-24 | 2016-07-19 | Stichting Het Nederlands Kanker Instituut | Composition |
WO2010020799A2 (fr) * | 2008-08-22 | 2010-02-25 | Slotervaart Participaties Bv | Composition |
BRPI0906467C1 (pt) * | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
CN101632630A (zh) * | 2008-07-24 | 2010-01-27 | 北京诺美医药科技有限公司 | 一种普罗布考固体分散体 |
JP5751868B2 (ja) * | 2010-03-30 | 2015-07-22 | 日東電工株式会社 | フィルム状製剤及びその製造方法 |
MX2012014387A (es) * | 2010-06-09 | 2013-05-01 | Abbvie Inc | Dispersiones solidas que contienen inhibidores de cinasa. |
MX347512B (es) * | 2010-11-19 | 2017-04-28 | Gilead Sciences Inc | Composiciones terapeuticas que comprenden hcl de rilpivirina y fumarato de disoproxilo de tenofovir. |
WO2013040187A1 (fr) * | 2011-09-13 | 2013-03-21 | Isp Investments Inc. | Dispersion solide de composés peu solubles comprenant une crospovidone et au moins un polymère hydrosoluble |
CN102357075A (zh) * | 2011-09-30 | 2012-02-22 | 武汉平华生物医药科技有限公司 | 一种多西他赛纳米制剂及其制备方法 |
-
2014
- 2014-03-31 WO PCT/KR2014/002734 patent/WO2015152433A1/fr active Application Filing
-
2015
- 2015-03-20 PL PL15773354T patent/PL3125872T3/pl unknown
- 2015-03-20 CA CA2944438A patent/CA2944438C/fr active Active
- 2015-03-20 PT PT157733544T patent/PT3125872T/pt unknown
- 2015-03-20 EP EP15773354.4A patent/EP3125872B1/fr active Active
- 2015-03-20 KR KR1020167027373A patent/KR101851571B1/ko active IP Right Grant
- 2015-03-20 RU RU2016136636A patent/RU2684632C2/ru active
- 2015-03-20 MX MX2016012596A patent/MX2016012596A/es active IP Right Grant
- 2015-03-20 LT LTEP15773354.4T patent/LT3125872T/lt unknown
- 2015-03-20 HU HUE15773354A patent/HUE046616T2/hu unknown
- 2015-03-20 WO PCT/KR2015/002756 patent/WO2015152544A1/fr active Application Filing
- 2015-03-20 PE PE2016001849A patent/PE20161477A1/es unknown
- 2015-03-20 BR BR112016022528-7A patent/BR112016022528B1/pt active IP Right Grant
- 2015-03-20 MA MA39361A patent/MA39361B1/fr unknown
- 2015-03-20 US US15/300,515 patent/US9867801B2/en active Active
- 2015-03-20 DK DK15773354.4T patent/DK3125872T3/da active
- 2015-03-20 ES ES15773354T patent/ES2748686T3/es active Active
- 2015-03-20 CN CN201580016355.2A patent/CN106255496B/zh active Active
- 2015-03-20 MY MYPI2016001721A patent/MY175387A/en unknown
- 2015-03-20 AU AU2015242738A patent/AU2015242738B2/en active Active
- 2015-03-20 JP JP2016559161A patent/JP6539675B2/ja active Active
- 2015-03-20 SI SI201530891T patent/SI3125872T1/sl unknown
- 2015-03-20 CU CU2016000144A patent/CU24486B1/es unknown
- 2015-03-20 SG SG11201607456RA patent/SG11201607456RA/en unknown
- 2015-03-20 UA UAA201609267A patent/UA117610C2/uk unknown
- 2015-03-27 UY UY0001036055A patent/UY36055A/es not_active Application Discontinuation
- 2015-03-30 TW TW104110283A patent/TWI706793B/zh active
- 2015-03-30 AR ARP150100942A patent/AR099886A1/es unknown
-
2016
- 2016-09-19 PH PH12016501825A patent/PH12016501825A1/en unknown
- 2016-09-22 IL IL247977A patent/IL247977B/en active IP Right Grant
- 2016-09-27 DO DO2016000262A patent/DOP2016000262A/es unknown
- 2016-09-28 CL CL2016002441A patent/CL2016002441A1/es unknown
- 2016-09-29 SA SA516371952A patent/SA516371952B1/ar unknown
- 2016-09-30 GT GT201600208A patent/GT201600208A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39361B1 (fr) | Dispersion solide amorphe comprenant un taxane, comprimé contenant la dispersion, et méthode de préparation associée | |
MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
MA46337A (fr) | Composé de pyridine | |
EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
EA201991884A2 (ru) | Ингибиторы g12c kras | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
EA201691484A1 (ru) | Соли и твердая форма ингибитора btk | |
WO2016004305A3 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
MX2022004937A (es) | Inhibidores de las cinasas raf. | |
CR20160438A (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación | |
MX2020007554A (es) | Formulacion farmaceutica que comprende esomeprazol y bicarbonato de sodio. | |
EP4249071A3 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
MA38816A (fr) | Sulfamidase modifiée et sa production | |
JOP20180071A1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
EA201992004A1 (ru) | Способы предотвращения или лечения офтальмологических заболеваний | |
EA201990645A1 (ru) | Пиридо пятичленное ароматическое циклическое соединение, способ его получения и применение | |
WO2014141295A3 (fr) | Traitement et prophylaxie de maladies rénales | |
NZ712341A (en) | A crystalline form of an anxiolytic compound | |
WO2016069542A3 (fr) | Composés de lactone, leurs procédés de préparation et d'utilisation | |
WO2016004280A3 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
EP3459933A3 (fr) | Formes solides d'un compose pharmeceutiquement actif | |
WO2018119108A8 (fr) | Formulations pharmaceutiques solides d'asimadoline | |
WO2017064558A8 (fr) | Nouveau immunostimulant | |
WO2016167511A3 (fr) | Dérivé de n2-(2-méthoxyphényl)pyrimidine, procédé pour le préparer et composition pharmaceutique pour la prévention ou le traitement du cancer le contenant en tant qu'ingrédient actif |